Published in J Med Chem on July 24, 2012
Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem (2013) 1.03
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. ACS Med Chem Lett (2012) 0.90
KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One (2012) 0.86
Synthesis and Biological Investigation of some Novel Sulfonamide and Amide Derivatives Containing Coumarin Moieties. Iran J Pharm Res (2014) 0.75
Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. Bio Protoc (2017) 0.75
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc (2006) 8.42
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer (2011) 6.32
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Virtual computational chemistry laboratory--design and description. J Comput Aided Mol Des (2005) 3.83
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell (2004) 3.43
Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today (2007) 3.36
HIF-1 as a target for drug development. Nat Rev Drug Discov (2003) 3.07
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A (2009) 2.33
Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res (2001) 2.14
Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 program. J Chem Inf Comput Sci (2002) 1.81
Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med (2009) 1.74
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res (2005) 1.73
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res (2006) 1.66
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene (2005) 1.61
Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax (2009) 1.57
Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs (2005) 1.52
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther (2008) 1.52
Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res (2006) 1.51
Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer (2010) 1.50
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res (2005) 1.49
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem (2009) 1.44
Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene (2006) 1.42
HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ (2011) 1.40
Computing chemistry on the web. Drug Discov Today (2005) 1.33
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol (2002) 1.29
Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci (2001) 1.26
Estimation of aqueous solubility of chemical compounds using E-state indices. J Chem Inf Comput Sci (2001) 1.25
Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med (2009) 1.23
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 1.20
An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J Med Chem (2010) 1.20
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res (2004) 1.19
Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res (2008) 1.19
HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer (2009) 1.17
Current trends in lead discovery: are we looking for the appropriate properties? Mol Divers (2002) 1.16
A convenient preparation of heteroaryl sulfonamides and sulfonyl fluorides from heteroaryl thiols. J Org Chem (2006) 1.14
A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene (2003) 1.12
Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther (2004) 1.11
(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors. J Med Chem (2007) 1.10
Inhibitors of hypoxia-inducible factor-1 signaling. Curr Opin Investig Drugs (2006) 1.04
Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Berl) (2009) 1.01
Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg Med Chem Lett (2011) 1.01
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther (2008) 1.00
Inhibition of hypoxia inducible factor by phenethyl isothiocyanate. Biochem Pharmacol (2009) 1.00
A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer (1993) 0.98
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Impact of HIF-1alpha and HIF-2alpha on proliferation and migration of human pulmonary artery fibroblasts in hypoxia. FASEB J (2005) 0.97
Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol (2008) 0.95
Synthesis and structure-phytotoxicity relationships of acetylenic phenols and chromene metabolites, and their analogues, from the grapevine pathogen Eutypa lata. J Nat Prod (2003) 0.93
p16 Modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Invest (2010) 0.91
Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. ACS Med Chem Lett (2012) 0.90
Natural chromenes and chromene derivatives as potential anti-trypanosomal agents. Biol Pharm Bull (2008) 0.87
KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One (2012) 0.86
Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line. J Biol Chem (2010) 0.80
Antipyretic, analgesic, anti-inflammatory and antioxidant activities of two major chromenes from Melicope lunu-ankenda. J Ethnopharmacol (2010) 0.76
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Natural mutagenesis of human genomes by endogenous retrotransposons. Cell (2010) 5.50
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol (2005) 3.42
Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med (2007) 2.83
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res (2008) 2.81
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol (2004) 2.71
Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res (2005) 2.59
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol (2009) 2.50
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol (2006) 2.37
The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science (2004) 2.18
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem (2004) 2.09
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest (2004) 2.03
Functional interaction between paramyxovirus fusion and attachment proteins. J Biol Chem (2008) 1.78
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. IEEE Trans Biomed Eng (2011) 1.63
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res (2002) 1.62
Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol (2004) 1.61
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene (2005) 1.61
Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits. Chem Biol (2012) 1.60
Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol (2004) 1.58
Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene (2002) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol (2007) 1.56
Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs (2005) 1.52
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
Probing the spatial organization of measles virus fusion complexes. J Virol (2009) 1.50
Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry (2012) 1.48
EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs (2005) 1.48
PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J Biol Chem (2004) 1.47
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem (2007) 1.42
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res (2007) 1.38
Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J Mol Biol (2010) 1.37
The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs. Proc Natl Acad Sci U S A (2004) 1.37
Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res (2003) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation. J Am Chem Soc (2007) 1.34
Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther (2006) 1.34
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther (2006) 1.33
Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci (2005) 1.33
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology (2011) 1.30
A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med (2007) 1.29
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol (2002) 1.29
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res (2005) 1.28
Highly active anticancer curcumin analogues. Adv Exp Med Biol (2007) 1.27
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One (2013) 1.25
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol (2012) 1.25
Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther (2004) 1.24
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.24
Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother (2007) 1.24
Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med (2009) 1.23
EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle (2008) 1.23
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res (2009) 1.22
An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates. J Virol (2005) 1.22
Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol (2003) 1.21
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. Am J Nucl Med Mol Imaging (2013) 1.21
Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 1.20
Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol (2005) 1.20
Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci (2003) 1.20
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res (2004) 1.19
Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci (2010) 1.18
Development of a unique small molecule modulator of CXCR4. PLoS One (2012) 1.18
A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18
Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One (2011) 1.18
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav (2008) 1.17
Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol (2011) 1.17
Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target (2008) 1.17
Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17
Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res (2004) 1.16
The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle (2005) 1.16
Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res (2006) 1.13
Paclitaxel binding to human and murine MD-2. J Biol Chem (2008) 1.13
Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med (2003) 1.13
A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene (2003) 1.12
Discovery of small molecule CXCR4 antagonists. J Med Chem (2007) 1.12
Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot (2003) 1.11
Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol (2005) 1.11
Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem (2006) 1.11
Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med (2007) 1.11
Role of the highly conserved middle region of prion protein (PrP) in PrP-lipid interaction. Biochemistry (2010) 1.11
Nonpeptide inhibitors of measles virus entry. J Med Chem (2006) 1.08
Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem (2010) 1.08